Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 5908656, 10 pages
http://dx.doi.org/10.1155/2016/5908656
Review Article

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?

1Cardiometabolism and Nutrition Institute (ICAN), Heart and Metabolism Department, Pitié-Salpêtrière Hospital (APHP), 75013 Paris, France
2INSERM UMRS U1166 (Eq 6) Nutriomics, UPMC, Pierre et Marie Curie Faculty Paris 6, Sorbonne University, 75013 Paris, France

Received 10 February 2016; Accepted 18 May 2016

Academic Editor: Fabrizio Barbetti

Copyright © 2016 Chloé Amouyal and Fabrizio Andreelli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Eissele, R. Göke, S. Willemer et al., “Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man,” European Journal of Clinical Investigation, vol. 22, no. 4 I, pp. 283–291, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Tolhurst, F. Reimann, and F. M. Gribble, “Nutritional regulation of glucagon-like peptide-1 secretion,” Journal of Physiology, vol. 587, no. 1, pp. 27–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Theodorakis, O. Carlson, S. Michopoulos et al., “Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 3, pp. E550–E559, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-J. Cho, S. Kosari, B. Hunne et al., “Differences in hormone localisation patterns of K and L type enteroendocrine cells in the mouse and pig small intestine and colon,” Cell and Tissue Research, vol. 359, no. 2, pp. 693–698, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. F. K. Knop, T. Vilsbøll, S. Larsen et al., “Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution,” American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 1, pp. E324–E330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Mortensen, L. L. Christensen, J. J. Holst, and C. Orskov, “GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine,” Regulatory Peptides, vol. 114, no. 2-3, pp. 189–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Little, N. J. Isaacs, R. L. Young et al., “Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 307, no. 10, pp. G958–G967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Svendsen, R. Pais, M. S. Engelstoft et al., “GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness,” Journal of Endocrinology, vol. 228, no. 1, pp. 39–48, 2016. View at Publisher · View at Google Scholar
  9. K. L. Egerod, M. S. Engelstoft, K. V. Grunddal et al., “A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin,” Endocrinology, vol. 153, no. 12, pp. 5782–5795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. V. Grunddal, C. F. Ratner, B. Svendsen et al., “Neurotensin is coexpressed, coreleased, and acts together with GLP-1 and PYY in enteroendocrine control of metabolism,” Endocrinology, vol. 157, no. 1, pp. 176–194, 2016. View at Publisher · View at Google Scholar
  11. L. A. Knudsen, N. Petersen, T. W. Schwartz, and K. L. Egerod, “The MicroRNA repertoire in enteroendocrine cells: identification of miR-375 as a potential regulator of the enteroendocrine lineage,” Endocrinology, vol. 156, no. 11, pp. 3971–3983, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Herrmann, R. Göke, G. Richter, H.-C. Fehmann, R. Arnold, and B. Göke, “Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients,” Digestion, vol. 56, no. 2, pp. 117–126, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Drucker, T. Jin, S. L. Asa, T. A. Young, and P. L. Brubaker, “Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line,” Molecular Endocrinology, vol. 8, no. 12, pp. 1646–1655, 1994. View at Google Scholar · View at Scopus
  14. J. Abello, F. Ye, A. Bosshard, C. Bernard, J.-C. Cuber, and J.-A. Chayvialle, “Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line,” Endocrinology, vol. 134, no. 5, pp. 2011–2017, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. R. A. Reimer, C. Darimont, S. Gremlich, V. Nicolas-Métral, U. T. Rüegg, and K. Macé, “A human cellular model for studying the regulation of glucagon-like peptide-1 secretion,” Endocrinology, vol. 142, no. 10, pp. 4522–4528, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Reimann and F. M. Gribble, “Glucose-sensing in glucagon-like peptide-1-secreting cells,” Diabetes, vol. 51, no. 9, pp. 2757–2763, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. L. B. Nielsen, K. B. Ploug, P. Swift et al., “Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes,” European Journal of Endocrinology, vol. 156, no. 6, pp. 663–671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. F. M. Gribble, L. Williams, A. K. Simpson, and F. Reimann, “A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line,” Diabetes, vol. 52, no. 5, pp. 1147–1154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Ritzel, A. Fromme, M. Ottleben, U. Leonhardt, and G. Ramadori, “Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum,” Acta Diabetologica, vol. 34, no. 1, pp. 18–21, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Rozengurt and C. Sternini, “Taste receptor signaling in the mammalian gut,” Current Opinion in Pharmacology, vol. 7, no. 6, pp. 557–562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. F. Margolskee, J. Dyer, Z. Kokrashvili et al., “T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15075–15080, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. D. Dotson, L. Zhang, H. Xu et al., “Bitter taste receptors influence glucose homeostasis,” PLoS ONE, vol. 3, no. 12, article e3974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W.-C. Hsueh, B. D. Mitchell, R. Aburomia et al., “Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study,” Diabetes Care, vol. 23, no. 5, pp. 595–601, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bose, B. Oliván, J. Teixeira, F. X. Pi-Sunyer, and B. Laferrère, “Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?” Obesity Surgery, vol. 19, no. 2, pp. 217–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Manning, A. Pucci, and R. L. Batterham, “GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery?” Physiology, vol. 30, no. 1, pp. 50–62, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Prasad-Reddy and D. Isaacs, “A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond,” Drugs in Context, vol. 4, Article ID 212283, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Wang, Z. Gou, F. Wang, M. Nling, and S.-D. Zhai, “Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies,” PLoS ONE, vol. 9, no. 8, article e103798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Andreelli, C. Amouyal, C. Magnan, and G. Mithieux, “What can bariatric surgery teach us about the pathophysiology of type 2 diabetes?” Diabetes & Metabolism, vol. 35, no. 6, part 2, pp. 499–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Troy, M. Soty, L. Ribeiro et al., “Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice,” Cell Metabolism, vol. 8, no. 3, pp. 201–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Schirra, K. Sturm, P. Leicht, R. Arnold, B. Göke, and M. Katschinski, “Exendin(9–39)amide is an antagonist of glucagon-like peptide-1(7–36)amide in humans,” Journal of Clinical Investigation, vol. 101, no. 7, pp. 1421–1430, 1998. View at Google Scholar
  32. M. L. Vetter, T. A. Wadden, K. L. Teff et al., “GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification,” Diabetes, vol. 64, no. 2, pp. 434–446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Ye, Z. Hao, M. B. Mumphrey et al., “GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 306, no. 5, pp. R352–R362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. H. E. Wilson-Pérez, A. P. Chambers, K. K. Ryan et al., “Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency,” Diabetes, vol. 62, no. 7, pp. 2380–2385, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. E. H. Starling, “The Croonian lectures on the chemical correlation of the functions of the body,” The Lancet, vol. 166, no. 4275, pp. 339–341, 1905. View at Publisher · View at Google Scholar
  36. B. Thorens, “Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. K. M. Heppner, M. Kirigiti, A. Secher et al., “Expression and distribution of glucagon-like peptide-1 receptor mrna, protein and binding in the male nonhuman primate (Macaca mulatta) brain,” Endocrinology, vol. 156, no. 1, pp. 255–267, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Pyke, R. S. Heller, R. K. Kirk et al., “GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody,” Endocrinology, vol. 155, no. 4, pp. 1280–1290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. D. D'Alessio, W. Lu, W. Sun et al., “Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system,” American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, vol. 293, no. 6, pp. R2163–R2169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Trapp and J. E. Richards, “The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?” Current Opinion in Pharmacology, vol. 13, no. 6, pp. 964–969, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Buhmann, C. W. le Roux, and M. Bueter, “The gut–brain axis in obesity,” Best Practice & Research Clinical Gastroenterology, vol. 28, no. 4, pp. 559–571, 2014. View at Publisher · View at Google Scholar
  43. B. Ahrén, “Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 286, no. 2, pp. R269–R272, 2004. View at Google Scholar · View at Scopus
  44. A. S. Rocca and P. L. Brubaker, “Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion,” Endocrinology, vol. 140, no. 4, pp. 1687–1694, 1999. View at Google Scholar · View at Scopus
  45. A. Plamboeck, S. Veedfald, C. F. Deacon et al., “The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 304, no. 12, pp. G1117–G1127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Plamboeck, S. Veedfald, C. F. Deacon et al., “Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty,” European Journal of Endocrinology, vol. 169, no. 2, pp. 187–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Thorens and P. J. Larsen, “Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 471–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Burcelin, W. Dolci, and B. Thorens, “Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization,” Diabetes, vol. 49, no. 10, pp. 1635–1642, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Burcelin, W. Dolci, and B. Thorens, “Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice,” Diabetes, vol. 49, no. 10, pp. 1643–1648, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Burcelin, A. Da Costa, D. Drucker, and B. Thorens, “Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor,” Diabetes, vol. 50, no. 8, pp. 1720–1728, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Nakabayashi, M. Nishizawa, A. Nakagawa, R. Takeda, and A. Niijima, “Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1,” American Journal of Physiology—Endocrinology and Metabolism, vol. 271, no. 5, pp. E808–E813, 1996. View at Google Scholar · View at Scopus
  52. T. P. Vahl, M. Tauchi, T. S. Durler et al., “Glucagon-Like Peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats,” Endocrinology, vol. 148, no. 10, pp. 4965–4973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. J. J. Holst, M. Christensen, A. Lund et al., “Regulation of glucagon secretion by incretins,” Diabetes, Obesity and Metabolism, vol. 13, supplement 1, pp. 89–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M.-B. Toft-Nielsen, M. B. Damholt, S. Madsbad et al., “Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3717–3723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. J. S. Moon and K. C. Won, “Pancreatic α-cell dysfunction in type 2 diabetes: old kids on the block,” Diabetes and Metabolism Journal, vol. 39, no. 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. M. Cho, Y. Fujita, and T. J. Kieffer, “Glucagon-like peptide-1: glucose homeostasis and beyond,” Annual Review of Physiology, vol. 76, pp. 535–559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Nauck, M. M. Heimesaat, K. Behle et al., “Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 1239–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. C. M. B. Edwards, J. F. Todd, M. Mahmoudi et al., “Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39,” Diabetes, vol. 48, no. 1, pp. 86–93, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. U. Kielgast, J. J. Holst, and S. Madsbad, “Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function,” Diabetes, vol. 60, no. 5, pp. 1599–1607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Orskov, J. J. Holst, and O. V. Nielsen, “Effect of truncated glucagon-like peptide-1 [Proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach,” Endocrinology, vol. 123, no. 4, pp. 2009–2013, 1988. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Tornehave, P. Kristensen, J. Rømer, L. B. Knudsen, and R. S. Heller, “Expression of the GLP-1 receptor in mouse, rat, and human pancreas,” Journal of Histochemistry and Cytochemistry, vol. 56, no. 9, pp. 841–851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. R. S. Heller, T. J. Kieffer, and J. F. Habener, “Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas,” Diabetes, vol. 46, no. 5, pp. 785–791, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. U. Kielgast, M. Asmar, S. Madsbad, and J. J. Holst, “Effect of glucagon-like peptide-1 on α- and β-cell function in C-peptide-negative type 1 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2492–2496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Singh, C. Grötzinger, K. W. Nowak et al., “Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition,” Endocrinology, vol. 148, no. 8, pp. 3887–3899, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. D. A. D'Alessio, W. Y. Fujimoto, and J. W. Ensinck, “Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures,” Diabetes, vol. 38, no. 12, pp. 1534–1538, 1989. View at Publisher · View at Google Scholar · View at Scopus
  66. G. P. Fadini, M. Albiero, L. Menegazzo, S. V. De Kreutzenberg, and A. Avogaro, “The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients,” Diabetes, Obesity and Metabolism, vol. 14, no. 6, pp. 518–522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. L. A. Scrocchi, T. J. Brown, N. MacLusky et al., “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene,” Nature Medicine, vol. 2, no. 11, pp. 1254–1258, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. L. A. Scrocchi, B. A. Marshall, S. M. Cook, P. L. Brubaker, and D. J. Drucker, “Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling,” Diabetes, vol. 47, no. 4, pp. 632–639, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Hansotia, A. Maida, G. Flock et al., “Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 143–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. D. A. Sandoval, D. Bagnol, S. C. Woods, D. A. D'Alessio, and R. J. Seeley, “Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake,” Diabetes, vol. 57, no. 8, pp. 2046–2054, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Hunter and C. Hölscher, “Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis,” BMC Neuroscience, vol. 13, article 33, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Sisley, R. Gutierrez-Aguilar, M. Scott, D. A. D'Alessio, D. A. Sandoval, and R. J. Seeley, “Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect,” Journal of Clinical Investigation, vol. 124, no. 6, pp. 2456–2463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. D. A. Sandoval and D. A. D'Alessio, “Physiology of proglucagon peptides: role ofglucagon and GLP-1 in health and disease,” Physiological Reviews, vol. 95, no. 2, pp. 513–548, 2015. View at Publisher · View at Google Scholar · View at Scopus